EU IMI and US Critical Path avoid duplication
This article was originally published in Scrip
Executive Summary
The EU Innovative Medicines Initiative has signed a memorandum of understanding with the Critical Path Institute (C-Path) in the US to further the shared objective the two public-private organisations have of accelerating the development of safer, more effective medicines.